EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties-Reference-Cited by-同舟云学术

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Published:2018-05-28 Issue:4 Volume:16 Page:429-432
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Dickson Rumona,Boland Angela,Duarte Rui^ORCID,Kotas Eleanor,Woolacott Nerys,Hodgson Robert,Riemsma Rob,Grimm Sabine,Ramaekers Bram,Joore Manuela,Büyükkaramikli Nasuh,Kaltenthaler Eva,Stevenson Matt,Pandor Abdullah,Edwards Steve,Hoyle Martin,Shepherd Jonathan,Armoiry Xavier,Brazzelli Miriam

Funder

Health Technology Assessment Programme

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

http://link.springer.com/article/10.1007/s40258-018-0393-7/fulltext.html

Reference13 articles.

1. European Medicines Agency. Pharmacovigilance: post authorisation 2018 [updated 2016; cited 2018 01 March]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000258.jsp&mid=WC0b01ac0580b18c76 .

2. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ. 2017;359:j4530.

3. National Institute for Health and Care Excellence. Technology appraisal guidance 2018. https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance .

4. McCabe C, Paul A, Fell G, Paulden M. Cancer Drugs Fund 2.0: a missed opportunity? PharmacoEconomics. 2016;34(7):629–33.

5. National Institute for Health and Care Excellence. Find NICE guidance 2018. https://www.nice.org.uk/guidance .

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk;BMJ Open;2023-03

2. A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England;Applied Health Economics and Health Policy;2022-12-20

3. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy;BMC Cancer;2022-12-05

4. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making;Value in Health;2021-04

5. Joining the Dots: Linking Disconnected Networks of Evidence Using Dose-Response Model-Based Network Meta-Analysis;Medical Decision Making;2021-01-15